COLL Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for COLL from our risk checks.
My Notes
NewNotes are coming soon
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.29 |
| 52 Week High | US$30.22 |
| 52 Week Low | US$14.04 |
| Beta | 0.74 |
| 1 Month Change | 21.94% |
| 3 Month Change | 57.69% |
| 1 Year Change | 61.84% |
| 3 Year Change | 40.64% |
| 5 Year Change | 25.18% |
| Change since IPO | 130.19% |
Recent News & Updates
Recent updates
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment
May 14Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings
May 13We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
May 01Read This Before Judging Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE
Feb 20Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jan 16Collegium Pharmaceutical (NASDAQ:COLL) Share Prices Have Dropped 27% In The Last Five Years
Dec 12
Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | -1.4% | 2.8% |
| 1Y | 61.8% | 4.5% | -9.2% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: COLL exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: COLL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 152 | Joe Ciaffoni | https://www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market Cap | US$949.75m |
| Earnings (TTM) | -US$42.84m |
| Revenue (TTM) | US$361.68m |
2.6x
P/S Ratio-22.2x
P/E RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$361.68m |
| Cost of Revenue | US$68.78m |
| Gross Profit | US$292.90m |
| Other Expenses | US$335.73m |
| Earnings | -US$42.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 80.98% |
| Net Profit Margin | -11.84% |
| Debt/Equity Ratio | 366.9% |
How did COLL perform over the long term?
See historical performance and comparison